louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03870191: Comparison of Therapeutic Effects of Trigger Point Injection and Twin Nerve Block in Chronic Myofascial Pain Patients
Official title: Comparison of Therapeutic Effects of Trigger Point Injection and Twin Nerve Block in Chronic Myofascial Pain Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Myofascial Pain - Dysfunction Syndrome of TMJ
Trigger Point Pain, Myofascial
Nerve Block
Lead sponsor: Rutgers University
Sponsor class: OTHER
First posted: 2019-03-12
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Maximum age (years): 89
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To see if there is there any difference in the treatment outcomes/results such as changes in pain intensity in patients with myofascial pain who have been treated with trigger point injections or twin block?

Detailed description: Most treatment approaches for chronic myofascial pain are not evidence-based. Studies are usually controversial. Most are short-term, non-randomized. An essential limitation has been the lack of standardization of diagnosis. Some studies do not differentiate between joint pain and muscle pain, which can significantly affect the outcome of the treatment provided.

Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) was recently published and validated. Their protocol allows standardization of the assessment and diagnosis of patients with temporomandibular disorder, including myofascial pain.

To the investigator's knowledge, no previous prospective, randomized study has been conducted demonstrating the treatment outcomes of either trigger point injections or twin block in patients with chronic myofascial pain.

Eligibility criteria: Inclusion Criteria:

* Patients diagnosed with Myofascial pain with referral based on the DC/TMD criteria
* Pain on the masseter and or temporalis muscles
* Pain present for at least 3 months

Exclusion Criteria:

* Generalized muscle disorder such as fibromyalgia
* Subjects on chronic pain medication
* Subjects who are known to have hypersensitivity to the local anesthetics.
* Pregnant women. A pregnancy test will not be given before subject enrollment. Women of childbearing ages will be asked verbally if they are pregnant. If they are unsure, then they will be excluded from the study.
* Subjects with cognitive problems e.g. Alzheimer's disease.

Primary outcomes:
measure: Pain relief: numerical pain scale
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Rutgers School of Dental Medicine
name: Rafeal Benoliel, BDS
role: STUDY_DIRECTOR
References:
citation: Ananthan S, Kanti V, Zagury JG, Quek SYP, Benoliel R. The effect of the twin block compared with trigger point injections in patients with masticatory myofascial pain: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2020 Mar;129(3):222-228. doi: 10.1016/j.oooo.2019.09.014. Epub 2019 Oct 13.
Clinical trial NCT06799091: Effect Of Neuromodulation In Patient With Fibromyalgia Syndrome
Official title: Effect Of Neuromodulation on Pain and Quality of Life In Patient With Fibromyalgia Syndrome
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Fibromyalgia
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2025-01-29
Enrollment: 40
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study was designed to examine the efficacy of Neuromodulation therapy By using transcutanous electric nerve stimulation( TENS) in Patients With FMS and to provide preliminary evidence regarding its effects on pain ,anxiety and QOL by objectively measuring Cortisol level in FMS patients.

Detailed description: Forty female patients with FM ( age : 20- 45 Years ) participated in the study after suing the consent form . Participants were randomly allocated assigned into 2 equal groups ( control group \[ G1 \] and low TENS group \[G2 \] ) . Group 1 received selected programs of Physiotherapy including Aerobic exercise and placebo low TENS. Group 2 received low frequency TENS (10 Hz).All participants were assessed for cortisol and pain level by using visual analogues scale Also participants were assessed for QOL by FIBROMYALGIA IMPACT QUESTIONNAIRE (FIQR) . treatment was done 3 sessions per weeks for successive 6 weeks pre and post assessment for all valuable were Done.

Eligibility criteria: Inclusion Criteria:

women between 20-45 years old, (ii) diagnoses according to the 2016 American College of Rheumatology criteria for fibromyalgia \[1\]

- Symptoms have been present at a similar level for at least three months (iii) Absence of other disorders that causes similar symptoms: systemic lupus erethromatosis (SLE), rheumatoid arthritis (RA) and Lyme disease based on laboratory investigations (erythrocyte sedimentation rate (ESR), Anti anti-cyclic citrullinated peptide (Anti CCP), antinuclear antibody (ANA) and Rheumatoid factor (RF)).

Exclusion Criteria:

* any medical, neurological, or psychiatric illness, use of strong opioids or other painkillers except paracetamol and/or ibuprofen, benzodiazepine, illicit drug or alcohol use, recent use of cannabis, pregnancy, breast feeding, and the presence of pain syndromes other than FM.

Presence of other autoimmune disorders e.g.: rheumatoid arthritis and systemic lupus erethromatosus

Primary outcomes:
measure: Cortisol level
timeFrame: Six weeks after begining of intervention
Secondary outcomes:
measure: Fibromyalgia impact questionaire
timeFrame: Six weeks after begining of intervention
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Faculty of physical therapy laps at cairo university
Study officials:
References:
Clinical trial NCT04498091: EPIdemiological Approaches to the Cardiovascular Consequences of COVID-19
Official title: EPIdemiological Approaches to the Cardiovascular Consequences of COVID-19
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Acute Myocardial Infarction
Lead sponsor: Centre Hospitalier Universitaire Dijon
Sponsor class: OTHER
First posted: 2020-08-04
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with acute type 2 MI

Brief summary: The COVID-19 pandemic highlights the importance of the prognosis of co-morbidities, such as coronary artery disease, which significantly increase the risk of mortality in patients infected with SARS-CoV2. Investigators have recently studied the complex links between respiratory infections, particularly pneumonia, and type 2 myocardial infarction (MI) in many respects. The etiology of type 2 MI is based on an imbalance of myocardial oxygen supply/need in the absence of rupture/erosion of atheromatous plaques. Based on the RICO survey data, the investigators investigated whether COVID-19-related sepsis and/or respiratory failure could be an underlying mechanism of MI2.


Eligibility criteria: Inclusion Criteria:

* patients hospitalized for a type 2 MI in CCU from CHU Dijon Bourgogne With or without pneumonia
* patients hospitalized for a type 2 MI in CCU from CHU Dijon Bourgogne With or without COVID 19

Exclusion Criteria:

* None

Primary outcomes:
measure: Characterizing type 2 myocardial infarction associated with CoV-2 SARS infection
timeFrame: Through study completion, an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Dijon
country: France
facility: Chu Dijon Bourgogne
Study officials:
References:
Clinical trial NCT02406391: Adherence to Preventive Care for Cervical Cancer
Official title: Adherence to Screening and Follow-up Diagnostic and Treatment Services for Cervical Cancer Prevention
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Cervical Cancer
Cervical Precancer
Adherence
Lead sponsor: Brookdale University Hospital Medical Center
Sponsor class: OTHER
First posted: 2015-04-02
Enrollment: 400
Sex: FEMALE
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Eligible patients who present to the gynecology clinic for a Pap smear exam or a colposcopy exam following an abnormal Pap smear.

Brief summary: In the United States, the highest incidence of cervical cancer occurs in inner city urban centers, rural areas, the deep South, Appalachia and the U.S.-Mexico border. The goal of this study is to study predictors of adherence among patients seeking care at an inner city medical center in New York City and the U.S. Mexico border for cervical cancer prevention, namely, Pap smears and colposcopy exams.

Detailed description: Because there are multiple pathways through which a person is influenced to seek and receive care, the investigators will conduct interviews with patients seeking care for cervical cancer prevention at an inner city medical center. The investigators will ask questions related to previous screening, diagnostic, and treatment practices as well as barriers experienced in seeking such care. The investigators will also explore patients' level of resiliency and coping as predictors of adherence to timely care. Furthermore, among immigrants, questions about acculturation and discrimination will be asked. Additional measures of socioeconomic status, such as education, income and occupation will also be collected.

Eligibility criteria: Inclusion Criteria:

* women who are at least 21 years old
* are seeking care for a Pap smear exam
* are seeking care for a colposcopy exam for the first time
* are not pregnant by self-report
* are able to provide informed consent

Exclusion Criteria:

* women who do not meet the above eligibility criteria
* women who have no prior history of a hysterectomy
* women who have previously participated in this study

Primary outcomes:
measure: Adherence to screening, colposcopy and follow-up treatment
timeFrame: 1-2 hour interview during clinic visit and review of patients' medical records during surveillance period (up to 2 years)
Secondary outcomes:
Other outcomes:
Locations:
city: Brooklyn
country: United States
facility: Brookdale University Hospital and Medical Center
state: New York
city: El Paso
country: United States
facility: University of Texas at El Paso
state: Texas
city: El Paso
country: United States
facility: Texas Tech University Health Science Center
state: Texas
Study officials:
affiliation: Brookdale University Hospital and Medical Center
name: Michele Follen, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00275691: Evaluation of Respiratory Specimens for Bacterial and Viral Pathogens by Real-Time PCR
Official title: Evaluation of Respiratory Specimens for Bacterial and Viral Pathogens by Real-Time PCR
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cough
Fever
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2006-01-12
Enrollment: 867
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Greater than 18 years of age. Cough present greater than one day and a history of fever and chills or documented fever in the Emergency Department

Brief summary: Community acquired pneumonia(CAP) is a common cause of morbidity and mortality. The diagnosis of CAP from the microbiology perspective has been challenging. Recent reports suggest the utility of real-time PCR for rapid and accurate diagnoses of these pathogens. Real-Time PCR tests, using the LightCycler instrument, will be performed on excess or additional specimens after extraction of nucleic acid.

Detailed description: Excess patient specimens normally collected for routine microbiologic testing for CAP and in some cases additional specimens (i.e.,blood, urine, throat swab) will be evaluated using real-time PCR tests developed in our laboratory. Specimens will be performed on patients suspect for CAP. Test will be directed at variety of pathogens including but not limited to M.pneumoniae, C. pneumoniae, Legionella pneumophila, Streptococcus pneumoniae, B. pertussis, influenza viruses, adenovirus, and metapneumovirus. The ultimate goal is to have a panel of highly accurate and rapid (same day) tests that can be orderable and performed in short period time for CAP cases.

Real-Time PCR tests, using the LightCycler instrument, will be performed on excess or additional specimens after extraction of nucleic acid. Real-time PCR tests, using the LightCycler instrument, will be performed on excess or additional specimens after extraction nucleic acid. These tests will include the organisms listed above. As nucleic acid extracts will be archived, other pathogens can be tested in the future should we develop additional real-time PCR tests. All results obtained by real-time PCR will be compared to results for conventional testing as listed above. Sensitivity, specificity and predictive values will be calculated. In cases where discordant results occur, additional PCR testing and or medical history review will be conducted.

Eligibility criteria: Greater than 18 years of age. Cough present greater than one day and a history of fever and chills or documented fever in the Emergency Department

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Franklin R. Cockerill, III, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06003491: Trial for Surgical Treatment of Reducible Atlantoaxial Dislocation
Official title: A Randomized Controlled Trial for Surgical Treatment of Reducible Atlantoaxial Dislocation
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Atlantoaxial Dislocation
Lead sponsor: Xuanwu Hospital, Beijing
Sponsor class: OTHER
First posted: 2023-08-22
Enrollment: 164
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The management of reducible atlantoaxial dislocation associated is challenging. Direct posterior distraction technique we proposed in 2010 could achieve satisfactory reduction. In 2020, we modified this technique and proposed a posterior intra-articular distraction technique. The intra-articular distraction technique could theoretically achieve satisfactory reduction and fusion. However, its superiority has not been proven. Therefore, we design a RCT study to compare the reduction rate and fusion rate of different strategies.


Eligibility criteria: Inclusion Criteria:

* CT indicated atlantoaxial dislocation Agree with the operation plan Agree to be followed up

Exclusion Criteria:

* The pathology is traumatic or RA Underwent operations in occipital-cervical region before With mortal diseases Without ability to sign papers

Primary outcomes:
measure: Fusion Rates
timeFrame: 12 months
Secondary outcomes:
measure: Japanese Orthopaedic Association Scores
timeFrame: 12 months
measure: Visual Analogue Scale
timeFrame: 12 months
measure: Neck Disability Index
timeFrame: 12 months
Other outcomes:
Locations:
Study officials:
References:
citation: Chen Z, Duan W, Chou D, Guan J, Liu Z, Jian Q, Zhang B, Bo X, Jian F. A Safe and Effective Posterior Intra-Articular Distraction Technique to Treat Congenital Atlantoaxial Dislocation Associated With Basilar Invagination: Case Series and Technical Nuances. Oper Neurosurg (Hagerstown). 2021 Mar 15;20(4):334-342. doi: 10.1093/ons/opaa391.
Clinical trial NCT00952991: The Effects of LAF237 on Gastric Function in Type 2 Diabetes
Official title: A Double Blind, Cross Over, Placebo Controlled, Multiple-dose Study to Evaluate the Effects of LAF237 on Gastric Emptying, Gastric Volume and Satiety in Patients With Type 2 Diabetes.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Diabetes Mellitus, Non-Insulin-Dependent
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
Collaborators: name: Novartis Pharmaceuticals
First posted: 2009-08-06
Enrollment: 18
Sex: ALL
Minimum age (years): 35
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Administration of the incretin hormone, Glucagon-Like-Peptide-1 (GLP-1), has been shown to enhance insulin secretion and suppress glucagon secretion in response to meal ingestion. In addition, GLP-1 also delays gastric emptying and has been shown to enhance gastric accommodation. These characteristics make GLP-1 an ideal therapy for type 2 diabetes (T2D). However, because of its rapid breakdown by dipeptidylpeptidase IV (DPP IV), GLP-1 has to be administered by continuous intravenous infusion. This would be a drawback in clinical usage. LAF237 is a synthetic inhibitor of DPP IV which has been shown to raise GLP-1 levels and potentiate meal-induced insulin secretion and glucagon suppression. However, the effects of LAF237 on gastric emptying and satiety are at present unknown. The investigators propose to study the effects of LAF237 on gastric emptying, gastric volume and satiety in patients with T2D in addition to examining the direct and indirect (mediated via insulin and glucagon) of this compound on postprandial glucose metabolism.


Eligibility criteria: Inclusion Criteria:

* Type 2 diabetes without microvascular or macrovascular complications treated with diet or up to 2 oral agents

Primary outcomes:
measure: Gastric Emptying
measure: Gastric accommodation
measure: Satiety
measure: Gastrointestinal Symptoms
Secondary outcomes:
measure: Meal Appearance Rate
measure: Glucose Disappearance
measure: Endogenous Glucose Production
measure: Insulin Secretion
measure: Glucagon Secretion
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
References:
Clinical trial NCT03380091: Metformin, Vitamin D, and Depression in Polycystic Ovary Syndrome (PCOS) Trial
Official title: Metformin, Vitamin D, and Depression in Polycystic Ovary Syndrome (PCOS) Trial: The MINDD Trial
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: PCOS
Depression
Vitamin D Deficiency
Insulin Resistance
Keywords: PCOS
Depression
Vitamin D
Insulin Resistance
Anxiety
Quality of life
Mood disorders
Lead sponsor: University of California, San Francisco
Sponsor class: OTHER
First posted: 2017-12-20
Enrollment: 5
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Open-label randomized clinical trial assessing the efficacy of Metformin versus Vitamin D in improving symptoms of depressed mood in polycystic ovary syndrome.

Detailed description: This is a single center, open-label, randomized, pilot clinical trial. Women with polycystic ovary syndrome and depressed mood, who are insulin resistant and vitamin D insufficient are eligible. Subjects are randomly assigned to one of two interventions: Vitamin D versus metformin. Subjects are followed with questionnaires and a final wrap-up clinic visit with a physician. The study duration is 12 weeks.

Eligibility criteria: Inclusion Criteria:

* Polycystic Ovary Syndrome diagnosis (Rotterdam Criteria)
* Vitamin D insufficiency (serum Vitamin D \<30 ng/mL)
* Insulin resistance
* Mild or greater severity of depression by Beck Depression Inventory-II

Exclusion Criteria:

* Current metformin use
* Vitamin D supplementation of \> 50,000 IU following confirmation of Vitamin D insufficiency
* Insulin-dependent diabetes mellitus
* Pregnancy or breastfeeding
* Untreated hypothyroidism
* Current active substance abuse
* Other major medical comorbidity: renal or hepatic dysfunction, severe pulmonary
* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data

Primary outcomes:
measure: Change From Baseline in Depression Score on the Beck Depression Inventory (BDI-II) at 12 Weeks
timeFrame: Baseline & 12 weeks
Secondary outcomes:
measure: Changes From Baseline Week in Insulin Resistance Score at Week 12.
timeFrame: Baseline week & week 12
measure: Change From Baseline in State-Trait Anxiety Inventory Score (STAI-S) at 12 Weeks
timeFrame: Baseline week & Week 12
measure: Changes From Baseline Week in Vitamin D 25-hydroxy Levels at Week 12.
timeFrame: Baseline week & week 12
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: UCSF Center for Reproductive Health
state: California
Study officials:
affiliation: University of California, San Francisco
name: Heather Huddleston, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00072891: Improving Medication Adherence in Comorbid Conditions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes Mellitus, Type 2
Hypertension
Hyperlipidemia
Keywords: Diabetes
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Sponsor class: NIH
First posted: 2003-11-14
Enrollment: 400
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP

Brief summary: This study is designed to study how adults with Type 2 Diabetes and either high blood pressure and/or high blood cholesterol manage their treatment regimen. It is also called the Diabetes Management Study. Individuals need to be 40 years of age or older and on oral medication (pills) management for two of the three conditions of interest. They may also be on other treatment such as insulin, diet and/or exercise programs. Individuals will be followed for approximately 12 months. About 1/4 of the persons in the study will receive a telephone counseling program with a nurse focused upon their management of their treatment program.


Eligibility criteria: * Type 2 diabetes mellitus, hypertension and/or hyperlipidemia,
* On oral medication for two of the above conditions,
* Manage own medications,
* Must have access to a telephone,
* Not participating in other adherence education or counseling trials

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Pittsburgh
country: United States
facility: University of Pittsburgh School of Nursing
state: Pennsylvania
Study officials:
References: